OBJECTIVES To analyse the utilisation of drugs for treatment of neurological disorder (ATC group: N01 – N07) within Slovakia between 1999 and 2007 and to asses the economic consequences of the medications. METHODS For 1999 - 2007, the data about consumption of drugs for treatment of neurological disorder were collected following ATC/DDD methodology. Data of wholesalers, who are legally obliged provide this information to the Slovak Institute for Drug Control, was used for the analysis. The results were expressed in the numbers of the packages, finance units (€) and defined daily doses per 1000 inhabitants per day (DID). RESULTS The collected data showed a significant increases in consumption of drugs for treatment of neurological disorder from 1999 to 2007 in term of DID (in 1999 (108.92), in 2003 (119.46) and in 2007 (142.57). A large increase in consumption of psychoanaleptics (in 1999 (16.00), in 2003 (33.22) and in 2007 (44.84) and a stable consumption of psycholeptics in 1999 (40.88), in 2003 (38.33) and in 2007 (41.34) in term of DID can be seen from this analysis. We can see a slight increase in consumption of drugs in term of DID within the group of antiepileptics (in 1999 (4.60), in 2003 (5.25) and in 2007 (6.86) and anti-parkinson drugs (in 1999 (3.19), in 2003 (3.81) and in 2007 (3.92). Financial expenditures for psychoanaleptics (in 1999 (€16,613,000), in 2003 (€40,572,000) and in 2007 (€30,382,000), for psycholeptics (in 1999 (€10,504,000), in 2003 (€24,603,000) and in 2007 (€36,502,000) can be seen from this study. CONCLUSIONS Inseparable components of the Slovak drug policy must be viewed realistically with regard to the consumption of drugs for neurological disorder. Adherence to principles of neurological treatment's guidelines lead to fundamental short and long term financial savings within health care systems.